Therefore, we sought to demonstrate resveratrol’s efficacy and dose-response effect in subjects with dyslipidemia in this randomized controlled trial, with lipid profile as the primary outcome and uric acid, XO activity, glucose, insulin, and oxidative stress biomarkers as the secondary outcomes. The gene discussed is XDH; the disease is metabolic syndrome.